Chengzhi Co., Ltd. (SHE:000990)
China · Delayed Price · Currency is CNY 6.47
-0.22 (-3.29%)
Sep 11, 2026, 3:04 PM CST
Chengzhi Revenue
Chengzhi had revenue of 3.31B CNY in the quarter ending June 30, 2026, with 10.99% growth. This brings the company's revenue in the last twelve months to 11.19B, down -1.69% year-over-year. In the year 2025, Chengzhi had annual revenue of 11.03B, down -0.35%.
Revenue (ttm)
11.19B
Revenue Growth
-1.69%
P/S Ratio
0.98
Revenue / Employee
2.51M
Employees
4,462
Market Cap
11.01B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.03B | -38.43M | -0.35% |
| Dec 31, 2024 | 11.07B | -1.35B | -10.88% |
| Dec 31, 2023 | 12.42B | 700.11M | 5.97% |
| Jan 1, 2023 | 11.72B | -466.63M | -3.83% |
| Jan 1, 2022 | 12.18B | 2.45B | 25.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Nanjing Vazyme Biotech | 1.47B |
| Shanghai Medicilon | 1.38B |
| Hualan Biological Vaccine | 1.19B |
| Mabwell (Shanghai) Bioscience | 873.99M |
| Sino Biological,Inc. | 768.00M |